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ThObjective: The long-term durability and hemodynamics of stentless valves are
largely unknown. In this study we prospectively analyzed 8-year clinical results with
the CryoLife-O’Brien Stentless Aortic Porcine Bioprosthesis (CryoLife Inc, Ken-
nesaw, Ga) and assessed its hemodynamic performance by serial echocardiography.
Methods: A total of 206 patients with a mean age of 72.8 years were followed up
prospectively after aortic valve replacement with the CryoLife-O’Brien stentless
bioprosthesis. Patients have been followed up from 2 to 96 months for mean 56
months. Echocardiography was performed by a single echocardiographer preoper-
atively, intraoperatively, postoperatively at discharge, 3 to 6 months later, and
annually thereafter.
Results: The 30-day operative mortality was 4.8%. Sixty-five percent of patients
received a valve 25 mm in diameter or larger, and 37% underwent concomitant
coronary bypass grafting. Twelve late deaths, none valve-related, have occurred.
Severe aortic insufficiency caused by oversizing led to early reoperation in 3
patients. The peak and mean systolic gradients decreased significantly during the
first 12 months after implantation (P .001), and the effective valve areas increased
significantly during this interval (P  .001). At 8 years, 2 patients have mild to
moderate aortic insufficiency. The actuarial survival at 8 years was 82%  3%. The
freedom from endocarditis was 100%, and the freedom from thromboembolic
events was 93%.
Conclusion: Despite more demanding surgical technique than with conventional
bioprostheses, the CryoLife-O’Brien bioprosthesis can be implanted safely in a
population predominantly older than 70 years at the time of the operation, with
excellent measures of hemodynamics, clinical outcomes, prosthesis durability, and
survival through 8 years.
Because several models of stentless xenografts have been introduced gradu-ally in clinical practice, any beneficial effect of these valves needs to beverified for every xenograft model. The objective of the CryoLife-O’Brien
Stentless Aortic Porcine Bioprosthesis (CryoLife Inc, Kennesaw, Ga) composite
design was to optimize hemodynamic performance and durability of bioprosthetic
valves. Three noncoronary leaflets are prepared by low-pressure glutaraldehyde
fixation process of less than 2 mm Hg. The scalloped design and the absence of
xenograft tissue below the leaflet hinge allow implantation with a single suture line.
Because there are no synthetic materials other than the suture, the risk of endocar-
ditis is expected to be reduced. Previously published reports confirm excellent
hemodynamics associated with this bioprosthesis.1-3 However, some studies have
suggested that this implant offers less satisfactory outcome than seen with standard
stentless models.4 This work represents a detailed standardized study that prospec-
tively evaluated the hemodynamic performance of the CryoLife-O’Brien biopros-
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diographer and analyzed the clinical outcomes of 206
patients who underwent aortic valve replacement (AVR) in
an 8-year experience of a single surgeon.
Patients and Methods
From September 1996 through September 2004, a total of 206
consecutive patients underwent AVR with the CryoLife-O’Brien
model 300 Stentless Aortic Porcine Bioprosthesis. The mean age
was 72.8  3 years, with a range of 65 to 84 years. All these
replacements were performed by the same surgeon. During the last
8 years, 1426 aortic prostheses were implanted , excepting double-
valve replacements. In 690 patients a mechanical valve was used,
and in 736, a tissue valve was used. A total of 402 stentless aortic
tissue valves were implanted by two surgeons. Stentless valves
accounted for approximately 58% of all tissue valves. Medtronic
Freestyle stentless bioprostheses (Medtronic, Inc, Minneapolis,
Minn) and St Jude Medical Toronto stentless porcine valve bio-
prostheses (St Jude Medical Canada, Mississauga, Ontario, Can-
ada) were also implanted. There were no special indications for
selection of each bioprosthesis, except for 20 patients who had a
disease of the ascending aorta in addition or were undergoing
reoperation because of endocarditis or valve degeneration; in those
cases, the Medtronic Freestyle prosthesis in full-root technique
was implanted. The contraindications for the implantation of the
CryoLife-O’Brien bioprosthesis were excessive calcification of the
aortic root and aortic root aneurysm. Patients have been followed
up from 2 to 96 months, mean 56 months. Patients were contacted
once a year.
Echocardiography was performed by the same echocardiogra-
pher preoperatively, intraoperatively, postoperatively at discharge,
TABLE 1. Selected preoperative patient characteristics
(n  206)
Age (mean  SD) 72.8 3
Male (No.) 89 (43%)
Hypertension 134 (65%)
Coronary artery disease (No.) 92 (45%)
Myocardial infarction (No.) 36 (17%)
Congestive heart failure (No.) 99 (48%)
New York Heart Association functional class
III or IV (No.)
168 (81%)
Diabetes mellitus (No.) 45 (22%)
Renal insufficiency (No.) 12 (6%)
Liver dysfunction (No.) 8 (4%)
Peripheral vascular disease (No.) 38 (18%)
Carotid atherosclerotic disease (No.) 25 (12%)
Stroke (No.) 37 (18%)
Smoking (No.) 56 (27%)
Chronic obstructive pulmonary disease (No.) 7 (18%)
Reoperation (No.) 15 (7%)
Pathology (No.)
Pure stenosis 62 (30%)
Primarily stenosis with insufficiency 107 (52%)
Pure insufficiency 37 (18%)3 to 6 months later, and annually thereafter. Mean values for each
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utive heartbeats in patients with sinus rhythmus and from five
beats in those in atrial fibrillation or a ventricular inhibited
pacemaker.
The effective orifice area (EOA) of the aortic valve was cal-
culated by the continuity equation, and the mean transvalvular
gradient at rest was derived from a simplified Bernoulli equation
accounting for the flow velocity across the left ventricular outflow
tract.5 Echocardiographic classification of aortic insufficiency was
in accordance with the criteria described by Perry and colleagues.6
The left ventricular mass (LVM) was calculated by the formula
introduced by Devereux and Reichek and was indexed for body
surface area to obtain the LVM index (LVMI).7 Selected preop-
erative patient characteristics are summarized in Table 1. The
surgical procedure consisted of a subcoronary supra-annular single
suture line technique, as has been described previously,8 and
remained constant throughout the study period without any
modifications.
The design of the CryoLife-O’Brien stentless bioprosthesis
allows the valve to be implanted in effective position such that a
prosthesis larger then the measured host annulus diameter can be
installed, independent of the indicated size. Oversizing by one size
(2 mm) was used in most patients; oversizing by two sizes was
used in 16 patients. Surgical intraoperative variables, including
aortic crossclamp time, cardiopulmonary bypass time, and valve
sizes, are listed in Table 2. Morbid and fatal valve-related events
were categorized as structural valve deterioration, nonstructural
valve dysfunction, thromboembolism, anticoagulant-related bleed-
ing events, prosthetic valve endocarditis, reoperation, valve-related
mortality, and all valve-related morbidity and mortality, according
to the framework devised by the Society for Thoracic Surgeons
and The American Association for Thoracic Surgery ad hoc
committee.9
Statistical Analysis
Data from individual patients were expressed as mean  SD, and
important ratios were expressed with 70% confidence limits. Com-
parisons between continuous variables were performed by repeat-
ed-measures analysis of variance to detect any significant changes
TABLE 2. Pertinent surgical parameters
Cardiopulmonary bypass time (min, mean  SD) 92  16
AVR 76  7
AVR plus coronary artery bypass grafting 112 9
Aortic crossclamp time (min, mean  SD) 62  9
AVR 51  8
AVR plus coronary artery bypass grafting 76 12
Coronary artery bypass grafting (No.) 76 (37%)
Valve size (mm)
21 (No.) 12 (6%)
23 (No.) 59 (29%)
25 (No.) 87 (42%)
27 (No.) 48 (23%)
Intra-aortic balloon pump support (No.) 16 (8%)
AVR, Aortic valve replacement.(in mean transvalvular gradient across the aortic valve prosthesis,
ptember 2005
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paired Student t test with Bonferroni correction. The actuarial
estimates were used to describe the time-related event-free rates
for death and other valve-related complications, and the variability
of these estimates is indicated by SEM.
Results
Clinical Outcomes
Sixty-five percent of patients received a valve 25 mm in
diameter or larger. Operative mortality rate at the time of
surgery was 0.5%. Rethoracotomy for bleeding had to be
performed in a total of 4 cases. None of the patients had
mediastinitis develop. The 30-day mortality was 4.8% 
2%. In the last consecutive 178 patients, the 30-day mor-
tality rate 2.2%. Among the first 28 patients, there were 6
in-hospital deaths (21.4%), with no deaths directly valve
related. Postmortem examination was performed in all 6
cases, and no technical or valve failure was demonstrated.
Three of these patients had undergone concomitant coro-
nary artery bypass grafting, and another 3 patients also had
associated morbidity. Causes of death were respiratory fail-
ure necessitating prolonged mechanical ventilation and sub-
sequent pneumonia in 2 patients, perioperative stroke with
severe neurologic deficit in 1 patient being readied for
hospital discharge, and prolonged intensive care stay be-
cause of low output syndrome after myocardial infarction
complicated by multiple organ failure in 3 patients with
concomitant coronary artery bypass grafting. Causes of late
deaths are shown in Table 3. Freedoms from death at 1 and
8 years after AVR were 95%  2% and 83%  3%,
respectively (Figure 1). Freedoms from cardiac mortality at
1 and 8 years, when noncardiac deaths were excluded, were
Figure 1. Freedom from death after AVR. Open circles
2001. Data are from National Statistics Bureau (Statistis
95% confidence interval of survival for patients with Cr
for each interval.
The Journal of Thoracic a97%  2% and 92%  2%, respectively (Figure 2). At last
follow-up, 96% of patients were in New York Heart Asso-
ciation functional class I or II, with a mean class of 1.09 
0.32 (vs 3.110.5 preoperatively, P  .001).
Valve-Related Complications
Freedom from structural valve deterioration at 8 years was
100%, and freedom from reoperation at 8 years was 98% 
1%. Severe aortic insufficiency led to early reoperation
because of technical reasons in 3 patients. All reoperated
valves were well positioned, but 2 of them with large
disparity between sinotubular and annular diameters had
central valvular incompetence. The third patient had para-
valvular incompetence, and torn suture was found intraop-
eratively at the site where the aortic annulus had significant
calcification. This valve was refixated, and the other 2 were
replaced with same model but one diameter number smaller.
Freedom from endocarditis at 8 years was 100%, whereas
freedom from thromboembolic complications at 8 years was
93%  3% (Figure 3). After implantation, permanent anti-
coagulation with warfarin was prescribed only if additional
atrial arrhythmia was present. Aspirin was routinely used
TABLE 3. Causes of late deaths
No.
Metastatic carcinoma 6
Myocardial infarction 3
Renal failure 1
Trauma 1
Sudden death 1
sent estimated survival for 73-year olds in Germany in
Bundesamt) Wiesbaden, 2004. Vertical line represents
-O’Brien valves; n indicates number of patients at riskrepre
ches
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bypass grafting. There were 11 documented thromboem-
bolic events. There were 3 late strokes and 5 late transient
ischemic attacks, none of which were fatal. The mean age of
these 8 patients was 81.5 years. Five had atrial arrhythmia
develop close to the time of the events, and hemodynami-
cally significant internal carotid stenosis was diagnosed in
4. Another 9 patients had late atrial arrhythmias develop; in
6 of them, warfarin therapy was initiated. None of patients
had clinically important anticoagulant-related bleeding
events.
Hemodynamic Outcomes
Table E1 summarizes the changes in mean aortic transval-
vular gradient as a function of time for all patients preop-
eratively, at discharge, at 6 months, and annually thereafter.
Table E2 summarizes the changes in EOA as a function of
Figure 2. Freedom from cardiac death; n indic777.e4 The Journal of Thoracic and Cardiovascular Surgery ● Setime for all patients preoperatively, at discharge, at 6
months, and annually thereafter. There were consistent de-
creases in mean aortic gradient as a function of time to
1-year follow-up. Thereafter, the values appeared to plateau.
There was a significant increase in EOA in the postoperative
series and again at 3 to 6 months. Analysis of variance
showed significantly larger EOA in larger valves, which
also was consistent throughout the follow-up period.
Left Ventricular Mass Index
LVMI with time is shown in Table E3. LVMI decreased
significantly early after AVR for all valve sizes. Between 2
and 6 years, there was a small but statistically not significant
increase in LVMI. The reason for this is probably multifac-
torial, but it may partially be related other coexisting mor-
bidities, such as hypertension (65% of patients).
number of patients at risk for each interval.
Figure 3. Freedoms from valve-related events of
endocarditis (filled circles) and thromboembolic
events (open diamonds); n indicates number of
patients at risk for each interval.atesptember 2005
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At 1 year of follow-up 92% of patients (179/195) had no
aortic regurgitation, 5% (10/195) had trivial regurgitation,
and 3% (6/195) had mild regurgitation. At 3 years, 85%
(141/166) had no aortic regurgitation, 12% (20/166) had
trivial regurgitation, and 3% (6/166) mild to moderate re-
gurgitation. At 5 years, 80% (100/125), 16% (20/125), and
4% (5/125) had no, trivial, and mild aortic regurgitation,
respectively. The last group represents the same patients
that had progression from trivial to mild regurgitation with
time and remained stable. Three of them were among the 12
patients with oversizing by two sizes, and that could be a
possible cause of aortic regurgitation. At 7 years of follow-
up, 88% of patients (45/51) had no aortic regurgitation, 8%
(4/54) had trivial regurgitation, and 5% (3/54) had mild to
moderate regurgitation. The aortic valve remained pliable in
all patients, and the leaflets did not change in thickness or
show evidence of calcification as assessed by
echocardiography.
Discussion
Clinical reports have demonstrated that the residual
transprosthetic pressure gradient after AVR for aortic ste-
nosis is a major risk factor for impaired left ventricular
diastolic dysfunction and incomplete postoperative regres-
sion of left ventricular hypertrophy.10-12 Through elimina-
tion of a rigid sewing ring, the dynamic nature of the aortic
root may be maintained after AVR with this device.13
Maintenance of normal aortic root function may at least in
part be responsible for the excellent hemodynamic perfor-
mances of both stentless valves, as well as aortic ho-
mografts.14 Stentless aortic bioprostheses were reintroduced
nearly 12 years ago to overcome the limited durability
observed after AVR with stented bioprostheses.15,16 Long-
term follow-up data now suggest that durabilities of stent-
less valves are comparable to those of stented bioprostheses.
Recently, Desai and coworkers17 have reported on about
200 patients with excellent early clinical results after AVR
with St Jude Medical Toronto stentless porcine valve bio-
prostheses but with significant increase in hazard for struc-
tural valve deterioration in late follow-up. Actuarial free-
dom from structural valve deterioration was 98.8% at 5
years but declined to 77.9% at 10 years. Luciani and col-
leagues4 have suggested unsatisfactory early outcomes with
the CryoLife-O’Brien stentless bioprosthesis relative to two
other stentless xenografts, although midterm survivals after
stentless AVR were good with all three xenografts.
In our series, CryoLife-O’Brien stentless bioprostheses
were implanted in a large number of patients, mostly older
than 70 years (85%) and were not implanted in patients
younger than 65 years. Follow-up has extended beyond 8
years for some. There are sufficient data on patients at
8-year follow-up to allow some inferences with regard to
The Journal of Thoracic athe performance of this bioprosthesis for replacement of the
aortic valve. Although most of the patients were elderly and
almost half had concomitant coronary artery disease, an
acceptable 30-day mortality of 4.8% was seen. For the age
(28% octogenarians at follow-up) and associated morbidity
of the patients with thromboembolic events, the thrombo-
embolic rate for the CryoLife-O’Brien stentless bioprosthe-
sis was low. Patients were not given warfarin sodium unless
there was persistent atrial fibrillation or flutter. Early throm-
boembolism was noted in only 1.5% of patients. The free-
dom from endocarditis was 100% at 8-year follow-up. This
indicates that the CryoLife-O’Brien stentless bioprosthesis
is quite resistant to infection, possibly because this device
has no synthetic materials other than suture, thereby reduc-
ing the possibility of foreign-body reaction and thus infec-
tion. Paravalvular leakage, not necessitating bioprosthesis
explantation and responding well to refixation, was ob-
served in 1 patient. Technical problems with oversizing in
the initial phase, causing central transvalvular gradient and
unacceptable hemodynamic performance, was the major
cause of early reoperation, necessitating bioprosthesis ex-
plantation in 2 patients. According to our opinion, disparity
is neither an absolute nor a relative contraindication for
implantation. The absolute contraindications for the implan-
tation of the CryoLife-O’Brien bioprosthesis were excessive
calcification of the aortic root and aortic root aneurysm. In
this study, structural deterioration was not observed. There
was a remarkable improvement in functional capacity after
the operation, with 95% of patients in New York Heart
Association functional class I or II, even though 85% of the
patients were in functional class III or IV before the oper-
ation. This remarkable improvement is likely related to the
excellent hemodynamic performance of the bioprosthesis,
probably because of its unique design. The selection of the
three noncoronary leaflets removes the unfavorable muscle-
based right coronary leaflet characteristics of the pig valve
such the EOA is maximized. Because there is no need for
external Dacron polyester fabric support or any additional
material of biologic or synthetic origin at the annulus level
of the xenograft, any unnecessary increase in the thickness
of the xenograft and any artificially induced stiffness or
stress on the tissue can be avoided.2 This study shows that
the low transvalvular gradients had reached their signifi-
cantly decreased maximum at 3-year follow-up and were
sustained at 4-year follow-up. EOA has been consistently
good, even in small valves. The very small 5-mm to 6-mm
cuff of xenograft aortic wall distal to the valve hinge and the
absence of a proximal cuff of this composite valve enable a
simple, rapid single suture line implantation technique. Be-
cause of this small aortic cuff, no problems have been
encountered with low-lying host coronary ostia. Additional
advantages of the supra-annular placement have included
good exposure for the small aortic root, provision of an
nd Cardiovascular Surgery ● Volume 130, Number 3 777.e5
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transvalvular gradients mimicking those of the homograft
valve.
Gelsomino and associates3 showed that left ventricular
hypertrophy resolves rapidly after the aortic valve is re-
placed with this bioprosthesis. In our study, the preoperative
values indicate minimal ventricular hypertrophy at the time
of implantation. The normal male value is 130 g/m2, and the
normal female is 100 g/m2. The preoperative values were
within the normal range, and the postoperative values were
considerably lower than normal throughout the 7-year eval-
uation. This is because LVM is indexed to body surface area
to allow comparisons between subjects of different size.
Estimation of LVM in obese subjects may therefore present
a challenge, given that indexing to body surface area may
normalize and thus incorrectly grossly underestimate LVM
measurements, as in our group of 75% obese patients. By
combining echocardiographic data with body composition
measurements in 3107 adults, Bella and coworkers18 were
able to demonstrate that LVM was more strongly related to
fat-free mass than to adipose mass, waist/hip ratio, body
mass index, or height-based surrogates for lean body
weight. They concluded that that LVM/fat-free mass criteria
could increase sensitivity to detect left ventricular
hypertrophy.
Study Limitations
This was an observational assessment of outcomes. The
patients were not randomly assigned to various therapies,
and comparison between inherently dissimilar groups is
problematic. Continued study will be necessary as patients
reach time points during which prosthesis failure is more
likely. Hemodynamic outcomes were measured only
through 7 years because of limited data available thereafter.
Conclusions
The CryoLife-O’Brien bioprosthesis appears to be a reliable
choice for a tissue valve in the aortic position, with very
good associated hemodynamics maintained through 7 years.
This valve has been implanted safely in a population pre-
dominantly older than 70 years, with excellent measures of
clinical outcomes and prosthesis durability. Survival thus
far is excellent and overlaps that of an age-matched
population.
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Martinovic et al Surgery for Acquired Cardiovascular DiseaseTABLE E1. Changes in mean aortic transvalvular gradient according to valve size
Size (mm)
Total21 23 25 27
Preoperative 58.6 16.4 47.4 16.1 43.8 17.2 47.6 18.8 48.8  16.4
Discharge 16.3 7.0 12.8 3.8 10.4 5.4 10.6 5.2 12.8  5.6*
3-6 mo 9.5 4.2 7.6 2.5 6.5 2.6 4.9 2.4 7.8  3.8*†
1 y 9.2  3.8 7.8 3.6 6.8 4.1 4.2 2.2 7.2  4*†
2 y 8.4  3.8 6.0 2.8 4.6 2.1 4.2 2.8 5.  3.2*†
3 y 6.4  2.6 4.8 2.4 3.6 2.0 4.3 3.1 4.9  2*†
4 y 6.8  2.8 2.7 1 3.4  2.1 4.8 3.6 4.8  3.2*†
5 y 7.1  2 5.2  2 4.6  2 5.1  2 4.6  2*†
6 y 6.4  2.6 4.7 2.4 4.8 2.4 4.9 2.5 4.4  2.4*†
7 y 7.2  2 5.8  2.3 3.8 2.4 4.8 2.4 5.2  2.5*†
Values are in millimeters of mercury (mean  SD). *P  .05 vs preoperative. †P  .05 vs discharge.
TABLE E2. Changes in EOA according to valve size
Size (mm)
Total21 23 25 27
Preoperative 0.54 0.18 0.78 0.25 0.88 0.48 1.10 0.681 0.76  0.46
Discharge 1.32 0.32 1.48 0.28 1.78 0.42 1.98 0.54 1.58 0.4*
3-6 mo 1.54 0.36 1.74 0.28 2.28 0.58 2.60 0.64 1.91 0.5*†
1 y 1.48 0.28 1.78 0.33 2.34 0.64 2.58 0.65 1.94 0.7*†
2 y 1.62 0.36 1.86 0.34 2.32 0.44 2.76 0.7 1.97 0.7*†
3 y 1.61 0.4 1.98 0.3 2.3 0.48 2.7 0.68 2.2  0.7*†
4 y 1.59 0.34 2.24 0.52 2.45 1.16 2.74 0.9 2.23 0.8*†
5 y 1.5  0.32 2.15 0.42 2.4 0.94 2.8 1.12 2.3 0.7*†
6 y 1.61 0.4 2.06 0.3 2.42 1.04 2.73 0.68 2.23 0.7*†
7 y 1.41 0.3 1.98 0.3 2.3 0.98 2.74 0.64 2.24 0.7*†
Values are in square centimeters (mean  SD). *P  .05 vs preoperative. †P  .05 vs discharge.
TABLE E3. Changes in LVMI according to valve size
Size (mm)
Total21 23 25 27
Preoperative 104 32 122 31 126 33 123 32 121  31
Discharge 96 13 116  28 116 19 118 32 111  26*
3-6 mo 89 28 101  36 110 29 98 33 99  30*
1 y 83  18 99 24 94 31 82 18 86  26*†
2 y 82  23 98 27 97 23 87 14 92  23*†
3 y 84  20 87 25 102  58 90 30 94  33*
4 y 83  36 88 14 104  30 92 25 91  25*
5 y 84  23 90 28 105  26 94 17 96  24*†
6 y 87  23 97 28 104  26 98 17 97  25*†
7 y 84  23 94 31 102  58 96 24 96  25*†Values are in grams per square meter (mean  SD). *P  .05 vs preoperative. †P  .05 vs discharge.
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